376TiP - A study of multiple-antigen specific cellular therapy in vitro combined with PD-1 antibody technology (MASCT-I) in patients with advanced solid tum...

Date 18 November 2017
Event ESMO Asia 2017 Congress
Session Poster lunch
Topics Basic Science
Cancer Immunology and Immunotherapy
Presenter Xing Zhang
Citation Annals of Oncology (2017) 28 (suppl_10): x111-x112. 10.1093/annonc/mdx666
Authors X. Zhang, X. Zhang, D. Weng, J. Xia, R. Xu
  • Biology Treatment Department, Sun Yat-sen university affiliated oncology hospital, 510060 - Guangzhou/CN



Tumor-specific immune responses are known to be initiated by dendritic cells (DCs) that can effectively process and present tumor antigens to CD4+ and CD8+ T cells, eliciting anti-tumor immune responses. MASCT-I technology is a sequential immune cell therapy for cancer treatment, which involves multiple antigen-loaded DC vaccines followed by the adoptive transfer of anti-tumor effector T cells. Patient autologous PBMC-derived DCs are in vitro loaded with multiple tumor antigen peptides to acquire DC vaccines. A part of DC vaccines are injected into patients to induce anti-tumor immunity in vivo. The other part of DCs is co-cultured with autologous PBMCs to induce tumor-specific effector T cells in vitro. During the co-culture, anti-PD1 antibody is included to block immunosuppressive PD1 signal, which can robustly boost anti-tumor efficacy of T cells. Obtained tumor-specific effector T cells are then infused into the patient to further inhibit tumor growth.

Trial design

This is a single center, sequential three stages phase I study. 3 + 3 design is used for stage 1 and 2. Stage1 will enroll patients with advanced (unresectable) or recurrent bladder cancer or soft tissue sarcoma who have failed all standard therapies, Patients will be treated with MASCT-I. If the DLT in the first cycle of MASCT-I is 

Clinical trial identification


Legal entity responsible for the study

HRYZ Biotech Co.


HRYZ Biotech Co.


All authors have declared no conflicts of interest.